5 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary BypassBlood Protein Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, hematologic disorder, hereditary antithrombin deficiency, hereditary disease, inherited blood coagulation disorder, thrombophiliaRecruitingPhase 32026-09-28NCT06096116
Cerebellar Mutism Syndrome StudyNeoplasms by Site, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, central nervous system cancer, central nervous system disorder, communication disorder, language disorder, mutism, neoplasm, nervous system disorder, neurodevelopmental disorder, psychiatric disorder, speech disorderRecruitingNot stated2026-08-12NCT02300766
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)lung disorder, pulmonary arterial hypertension, pulmonary hypertension, respiratory system disorderRecruitingPhase 32026-07-29NCT06274801
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)Anemia, Hypochromic, Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases, Iron Deficiencies, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, anemia, chronic renal failure syndrome, hematologic disorder, iron deficiency anemia, iron metabolism disease, kidney disorder, kidney failure, metabolic disease, urinary system disorderRecruitingPhase 32026-04-17NCT03619850
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasmActive, not recruitingPhase 32026-03-18NCT06726265